No company description available.
Join Vor in tackling autoimmune disease at its root by advancing telitacicept, a first- and potentially best-in-class dual BAFF/APRIL inhibitor. Contribute directly to a medicine with best-in-disease Phase 3 results in myasthenia gravis and expansion into multiple autoimmune diseases.
Vor Bio